EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial

Yanyan Liu, Ningjing Lin, Shuhua Yi, Huiqiang Huang, Ye Guo, Qingyuan Zhang, Haiyan Yang, Huilai Zhang iD, Liling Zhang, Ru Feng, Yijiao Qian, Jiankun Zhu und 2 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35339 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Yanyan Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Pyrimidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi), demonstrated clinically meaningful antitumor responses in covalent BTKi pretreated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the global phase 1/2 BRUIN study. In this multi‐center, open‐label, phase 2 trial, we investigated the efficacy and safety of pirtobrutinib in Chinese patients with BTKi pretreated relapsed/refractory (R/R) MCL, CLL/SLL, or other B‐cell malignancies. All patients received pirtobrutinib once daily in continuous 28‐day cycles. The primary endpoint was the overall response rate (ORR). Efficacy was assessed in patients with MCL and CLL/SLL with prior BTKi treatment and safety in all enrolled patients who received at least one dose of pirtobrutinib. Among 35 patients with covalent BTKis (cBTKi) pretreated MCL, the ORR was 62.9% (95% CI: 44.9, 78.5), the median duration of response (DOR) was not reached, and the 12‐month DOR rate was 59.7% (95% CI: 35.3, 77.5). Among 11 patients with cBTKi pretreated CLL/SLL, the ORR was 63.6% (95% CI: 30.8, 89.1), and the 12‐month DOR rate was 83.3% (95% CI: 27.3, 97.5). The most common adverse events in the safety population ( n = 87) were anemia (32.2%) and neutrophil count decreased (31.0%). Grade ≥3 hemorrhage occurred in 2.3% of patients and there were no cases of atrial fibrillation/flutter. Pirtobrutinib demonstrated clinically meaningful efficacy in Chinese patients with cBTKi pretreated R/R MCL, preliminary antitumor activity in Chinese patients with cBTKi pretreated R/R CLL/SLL and was generally well‐tolerated with no new safety signals observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-CellPyrimidinesProtein Kinase InhibitorsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedAdultAgammaglobulinaemia Tyrosine KinaseAged, 80 and overChinaDrug Resistance, NeoplasmPyrazolesEast Asian People

Stichwörter der Autor:innen

chronic lymphocytic leukemia/small lymphocytic lymphomamantle cell lymphomanoncovalent BTK inhibitorpirtobrutinib

Substanzen

PyrimidinesProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine KinasepirtobrutinibPyrazoles

Autor:innen und Institutionen

  • Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
  • Tianjin Institute of Health Science, Tianjin, China.
  • State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

ORCID-Profile: Huilai Zhang, Yuqin Song

Förderung

  • Eli Lilly and Company

Zitieren

APA

Liu, Y., Lin, N., Yi, S., Huang, H., Guo, Y., Zhang, Q., Yang, H., Zhang, H., Zhang, L., Feng, R., Qian, Y., Zhu, J., Song, Y., & Zhu, J. (2025). Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial. International Journal of Cancer. https://doi.org/10.1002/ijc.35339

Vancouver

Liu Y, Lin N, Yi S, Huang H, Guo Y, Zhang Q, et al. Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial. International Journal of Cancer. 2025. doi:10.1002/ijc.35339

BibTeX
@article{Liu2025,
  author = {Liu, Yanyan and Lin, Ningjing and Yi, Shuhua and Huang, Huiqiang and Guo, Ye and Zhang, Qingyuan and Yang, Haiyan and Zhang, Huilai and Zhang, Liling and Feng, Ru and Qian, Yijiao and Zhu, Jiankun and Song, Yuqin and Zhu, Jun},
  title = {Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35339}
}
Kostenlos starten →